Lilly Licenses Hormone Patch For Osteoporosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly Licenses Hormone Patch For Osteoporosis
You may also be interested in...
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
Amgen's osteoporosis and bone-related cancer drug denosumab may be one of the most eagerly-anticipated approvals of the year - not least by Amgen itself, whose future growth depends almost entirely on an FDA nod. But in another sense this antibody marks an ending, not a beginning